Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624853 | 0.86 | ALDH1A1 (0.44) | CASP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL16418462 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL28459787 | 0.79 | ALDH1A1 (0.44) | CASP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL1347657 | 0.76 | CASP1 (0.50) | CASP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL16546178 | 0.76 | TTR (0.53) | TSHRALDH1A1CYP3A4MAPTTDP1 | |
| SCHEMBL28832700 | 0.76 | CYP3A4 (0.46) | CASP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL28308098 | 0.76 | ALDH1A1 (0.46) | CASP1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL7357313 | 0.76 | ALDH1A1 (0.67) | TSHRALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL13643270 | 0.76 | ALDH1A1 (0.56) | TSHRALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL7290933 | 0.75 | ALDH1A1 (0.36) | CASP1TSHRALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | CASP1 520/4885TSHR 2803/4885ALDH1A1 934/4885 |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | CASP1 380/4885TSHR 4377/4885ALDH1A1 2620/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | CASP1 520/4885TSHR 2803/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.